PrimeGen Biotech Solidifies Position as Global Leader in Regenerative Medicine Research.

Alliances with Leading Scientists, Institutions and Corporations Reinforce Continued Commitment to Proprietary Germ Line Stem Cell

IRVINE, Calif. -- Amid ongoing discussion around America's place in the world of biomedical research, one U.S. company -- PrimeGen Biotech (www.primegenbiotech.com) - continues to steadily make its mark by becoming the global leader in the field of germ line stem cell (GSC) research and regenerative medicine applications.

Differentiating itself from published work to date, PrimeGen Biotech is home to the world's first laboratory to isolate and therapeutically reprogram human GSCs.

As one of only three known GSC research laboratories in the world, the company continues to invest in its proprietary PrimeCell technology and to ramp up the field of GSC research -- surpassing the work performed only in mouse models by laboratories outside the United States.

GSCs represent an especially promising adult-derived stem cell type, because of their uniquely protected niche in the body and their potential to be pluripotent--that is, to be able to be transformed into any cell or tissue type in the body.

Building on its successful in-vitro tests, PrimeGen Biotech is aggressively pursuing collaborations that are on track to result in the fastest, most responsible route for the development of cellular platforms for therapy. Partnering with well known scientists from independent labs, PrimeGen Biotech's cellular platforms have already been reliably reproduced.

The company has partnered with a leading academic institution to further develop germ cell reprogramming technology and advance pre-clinical animal models. This collaboration joins an earlier agreement reached with Regeneration Technologies, Inc. (RTI) (Nasdaq: RTIX), a Florida-based processor of orthopedic, cardiovascular and other biologic implants, to pursue orthopedic applications of the germ cell reprogramming technology.

"We are fully committed to the development of a next generation stem cell for therapeutic use," said Thomas C.K. Yuen, Chairman and CEO, PrimeGen Biotech. "Partnering with these leading organizations and institutions furthers our goal of moving from the laboratory to the bedside in the fastest and most responsible way."

The company also recently announced the appointment of Dr. Rudolph Jaenisch to its Scientific Advisory Board. A distinguished biomedical researcher and leader in epigenetic and transgenic science, Dr. Jaenisch is a founding member of the prestigious Whitehead Institute for Biomedical Research and professor of biology at the Massachusetts Institute of Technology. Upon accepting his appointment, Dr. Jaenisch said, "This research is significant and will contribute greatly to what is known about the developmental biology of the germ line and what its potential is for autologous cell based regenerative medicine."

About PrimeGen Biotech LLC 

PrimeGen Biotech LLC is a privately held regenerative medicine company dedicated to providing the most potent regenerative cells for use in diverse therapeutic applications. Its wholly owned subsidiary, PrimeCell[TM] Therapeutics LLC, has developed the first adult stem cell capable of transforming into any cell type found in the body - known as PrimeCell[TM]. PrimeGen's chairman and CEO Thomas C.K. Yuen is renowned for turning technological promise into successful, leading-edge companies - first as co-founder, co-chairman and COO of AST Research, Inc., then as chairman, CEO and president of SRS Labs.